PROTACs that target Bruton's tyrosine kinase have shown great response rates in B-cell cancers, and molecular glues that target Ikaros family proteins (IKZF1/3) are still helping people with blood cancers. Here, BTK is linked to hematopoietic and lymphoid system neoplasm.